Germany's Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its healthcare and industrial priorities, the decisions taken today will shape the sector’s competitiveness for decades to come. Dr Kai Joachimsen, CEO of the Bundesverband der Pharmazeutischen Industrie (BPI), discusses why…
My message is simply to continue believing in Europe Growth creates a different set of questions. Once commercial momentum is established, the challenge shifts from building a business to sustaining…
Professor Do-Youn Oh discusses advances in gastrointestinal oncology, reflecting on the practice-changing TOPAZ-1 trial, Korea’s strengths in clinical research, and the importance of biomarker-driven therapies. She shares her approach to…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors…
Long regarded as a clinical trials backwater, the Middle East has experienced a tremendous surge in clinical research over the past five years. This boom is fuelled by a global…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
The Middle East contains one of the world’s strongest concentrations of expertise in the rare blood disorder thalassaemia. The story starts with the high prevalence of this disease in the…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
See our Cookie Privacy Policy Here
